ArticleThe Kaohsiung journal of medical sciences2026
Rhaponticin Blocks Glycolysis-Mediated Histone Lactylation to Suppress Tongue Squamous Cell Carcinoma via HIF-1α Activity Inhibition.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Tongue squamous cell carcinoma (TSCC) often develops therapeutic resistance. Metabolic reprogramming, particularly the glycolysis/lactate/histone lactylation axis, is a critical driver of tumor progression and therapy resistance. This study investigated the anti-tumor mechanism of Rhaponticin (Rha), focusing on the metabolic/epigenetic axis involving hypoxia-inducible factor 1α (HIF-1α), glycolysis, and histone H3K18 lactylation (H3K18la). SCC9 and SCC9-CisR cells were treated with Rha alone or in combination with 2-deoxy-D-glucose (2-DG) or sodium lactate (LacNa). The effects of Rha on glycolysis and H3K18la were evaluated by extracellular acidification rate assays, glucose/lactate quantification, and western blotting. Gain- and loss-of-function studies targeting HIF-1α were conducted to determine the mechanistic dependency of Rha-mediated effects. Subcutaneous and liver metastasis xenograft models were established for in vivo validation. Rha significantly suppressed glycolysis, glucose consumption, and lactate production, concomitant with the downregulation of HK2, LDHA, GLUT1, and H3K18la levels. Rha not only mimicked the effects of 2-DG by inhibiting clonogenicity, migration, and invasion and decreasing cisplatin resistance in SCC9 or SCC9-CisR cells but also reversed LacNa-mediated promotion of these parameters, indicating that Rha acts through the glycolysis/lactate pathway. Rha inhibited tumor growth and liver metastasis, enhanced cisplatin sensitivity, and decreased H3K18la levels in mouse models. Mechanistically, Rha inhibited HIF-1α, thereby attenuating glycolytic flux and decreasing lactate-driven H3K18la. Rha inhibits TSCC progression and enhances cisplatin sensitivity by targeting HIF-1α and repressing the glycolysis/lactate/H3K18la axis, suggesting that Rha is a promising candidate for disrupting metabolic/epigenetic crosstalk in TSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.